Patient dosing has commenced in the Phase 1 clinical trial of SENTI-202 – Senti Biosciences

Tim Lu, Co-Founder and CEO at Senti Biosciences, shared the following post by Senti Biosciences on LinkedIn, adding the following:

“It’s been a tremendous effort by everyone at Senti Biosciences to advance our Logic Gate technology via SENTI-202 into Phase 1 clinical trials. We are very excited about the future and thank everyone who has supported us along the way.”

Quoting Senti Biosciences’ post:

“Today we announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf CAR-NK investigational cell therapy for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML). Learn more.”

Source: Tim Lu/LinkedIn and Senti Biosciences/LinkedIn
OncoDaily